Kubota Pharmaceutical Holdings is committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide.

Growth Strategy: To Develop an Innovative Portfolio of Ophthalmology Products

Development Pipeline:

  • Emixustat for Diabetic Retinopathy, Stargardt Disease and Intermediate AMD
  • Lanosterol for Cataract and Presbyopia
  • Optogenetics gene therapy for Retinitis Pigmentosa

New Development:

  • Partnering and in-licensing opportunities focused on innovative ophthalmic technologies
  • Build best in class exploratory development capabilities to address unmet medical needs


  • Kubota Pharmaceutical Holdings to leverage Acucela's broad-skilled employee base in research and development, while strengthening ties with the Japanese investment community
  • photo
  • photo
  • photo


  • To address unmet medical needs in sight-threatening diseases through scientific innovations
  • To build a unique company with continuous value creation for society
  • To create an excellent working environment and quality of life for employees